Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Wagner

Showing results (641-650 of 720) with videos related to

Pageof 72
Sort By:
Haematologica|April 27, 2023
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomesCharlotte B Wagner, Ken Boucher, Adrienne Nedved, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
Arquivos De Neuro-Psiquiatria|December 22, 2025
Epidemiology and healthcare access in Brazilian multiple sclerosis patients: insights from the BRANDO databaseAlfredo Damasceno, Cintia Ramari, Carlos Tauil, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Nature|November 2, 2018
Targeted neurotechnology restores walking in humans with spinal cord injuryFabien B Wagner, Jean-Baptiste Mignardot, Camille G Le Goff-Mignardot, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort studyNikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.
Haematologica|July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myelomaDanai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
The New England Journal of Medicine|June 11, 2020
Thrombectomy for Stroke in the Public Health Care System of BrazilSheila O Martins, Francisco Mont'Alverne, Letícia C Rebello, et al.
Pediatric Cardiology|June 29, 2023
The Fontan Udenafil Exercise Longitudinal Trial: Subgroup AnalysisDavid J Goldberg, Chenwei Hu, Adam M Lubert, et al.
Journal of the American Heart Association|August 12, 2025
Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc Analysis of the FUEL TrialDavid J Goldberg, Victor Zak, Chenwei Hu, et al.
Pageof 72

Showing results (641-650 of 720) with videos related to

Sort By:
Pageof 72
Haematologica|April 27, 2023
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomesCharlotte B Wagner, Ken Boucher, Adrienne Nedved, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
Arquivos De Neuro-Psiquiatria|December 22, 2025
Epidemiology and healthcare access in Brazilian multiple sclerosis patients: insights from the BRANDO databaseAlfredo Damasceno, Cintia Ramari, Carlos Tauil, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Nature|November 2, 2018
Targeted neurotechnology restores walking in humans with spinal cord injuryFabien B Wagner, Jean-Baptiste Mignardot, Camille G Le Goff-Mignardot, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort studyNikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.
Haematologica|July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myelomaDanai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
The New England Journal of Medicine|June 11, 2020
Thrombectomy for Stroke in the Public Health Care System of BrazilSheila O Martins, Francisco Mont'Alverne, Letícia C Rebello, et al.
Pediatric Cardiology|June 29, 2023
The Fontan Udenafil Exercise Longitudinal Trial: Subgroup AnalysisDavid J Goldberg, Chenwei Hu, Adam M Lubert, et al.
Journal of the American Heart Association|August 12, 2025
Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc Analysis of the FUEL TrialDavid J Goldberg, Victor Zak, Chenwei Hu, et al.
Pageof 72